Product:
AD RISK TEST is a non-invasive and affordable blood-based test kit for very early detection of the risk of developing Alzheimer’s Disease through APO-E4
Advantage:
AD RISK TEST detects the risk of Alzheimer’s years before symptoms without painful spinal puncture procedures, at a lower cost than competitors, with higher reliability.
Biocross’ kits are simple, provide rapid results, and are designed for easy incorporation into the clinical routine of hospitals and labs.
Biocross’ kits are simple, provide rapid results, and are designed for easy incorporation into the clinical routine of hospitals and labs.
Market opportunity:
80B€ in EU, USA, JP, AU (372 M people now in risk). Revenue comes from
royalties and down payments from licensed Pharma companies.
royalties and down payments from licensed Pharma companies.
Biocross offers a global, accurate diagnosis solution for all stages of different types of dementia development and distinguishes AD from other dementia
Commercial Status
Intellectual Property
WO granted, others pending
Tested in humans?
clinical validation done
FDA approval?
Exp. 18 months after next investment
CE approval?
Exp. November 2018
US reimbursement?
Possible, after FDA approval
EU reimbursement?
subject to analysis
Currently selling?
Plan to start sales in Spain in 2Q-2019
links of interest
